BRPI0507886A - método de purificação de albumina compreendendo uma etapa de nanofiltração, solução e composição para uso terapêutico contendo-o - Google Patents

método de purificação de albumina compreendendo uma etapa de nanofiltração, solução e composição para uso terapêutico contendo-o

Info

Publication number
BRPI0507886A
BRPI0507886A BRPI0507886-5A BRPI0507886A BRPI0507886A BR PI0507886 A BRPI0507886 A BR PI0507886A BR PI0507886 A BRPI0507886 A BR PI0507886A BR PI0507886 A BRPI0507886 A BR PI0507886A
Authority
BR
Brazil
Prior art keywords
solution
composition
purification method
therapeutic use
use containing
Prior art date
Application number
BRPI0507886-5A
Other languages
English (en)
Inventor
Paul Boulange
Sami Chtourou
Stephane Boyer
Roland Schmitthaeusler
Bruno Padrazzi
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34834103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0507886(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of BRPI0507886A publication Critical patent/BRPI0507886A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Water Supply & Treatment (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

MéTODO DE PURIFICAçãO DE ALBUMINA COMPREENDENDO UMA ETAPA DE NANOFILTRAçãO, SOLUçãO E COMPOSIçãO PARA USO TERAPêUTICO CONTENDO-O. A invenção se refere a um método de purificação de albumina compreendendo uma etapa que consiste em submeter uma solução aquosa de albumina, de concentração 15 g/L a 80 g/L e de pH de não menos do que 7, para uma nanofiltração em uma faixa de temperatura de entre 15 C a 55 C. A invenção ser refere igualmente a uma solução aquosa de albumina viralmente segura suscetível de ser obtida usando o método inventivo, no qual os sítios de transportes e de fixação dos princípios ativos terapêuticos da albumina são disponíveis e uma composição de albumina para uso terapêutico obtida por um tratamento de adaptação da dita solução de albumina para um uso clínico.
BRPI0507886-5A 2004-02-27 2005-02-23 método de purificação de albumina compreendendo uma etapa de nanofiltração, solução e composição para uso terapêutico contendo-o BRPI0507886A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0402001A FR2866890B1 (fr) 2004-02-27 2004-02-27 Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant
PCT/FR2005/000416 WO2005090402A1 (fr) 2004-02-27 2005-02-23 Procede de purificaton d’albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant

Publications (1)

Publication Number Publication Date
BRPI0507886A true BRPI0507886A (pt) 2007-08-07

Family

ID=34834103

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507886-5A BRPI0507886A (pt) 2004-02-27 2005-02-23 método de purificação de albumina compreendendo uma etapa de nanofiltração, solução e composição para uso terapêutico contendo-o

Country Status (16)

Country Link
US (3) US20070161122A1 (pt)
EP (1) EP1718673B1 (pt)
JP (2) JP4979571B2 (pt)
AT (1) ATE373014T1 (pt)
AU (1) AU2005223418B2 (pt)
BR (1) BRPI0507886A (pt)
CA (1) CA2557174C (pt)
CY (1) CY1107082T1 (pt)
DE (1) DE602005002461T2 (pt)
DK (1) DK1718673T3 (pt)
ES (1) ES2294696T3 (pt)
FR (1) FR2866890B1 (pt)
IL (1) IL177286A (pt)
PL (1) PL1718673T3 (pt)
PT (1) PT1718673E (pt)
WO (1) WO2005090402A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866890B1 (fr) * 2004-02-27 2008-04-04 Lab Francais Du Fractionnement Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
FR2894831B1 (fr) 2005-12-16 2008-02-15 Lab Francais Du Fractionnement Colle biologique exempte de thrombine et son utilisation comme medicament.
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
AU2011350895B2 (en) 2010-12-30 2015-05-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Glycols as pathogen inactivating agents
FR3004451B1 (fr) * 2013-04-11 2015-12-11 Lab Francais Du Fractionnement Procede de preparation d'une solution de proteine c viralement securisee par une double etape de nanofiltration
EP3119412A1 (en) * 2014-03-21 2017-01-25 Boreal Invest Terminal nanofiltration of solubilized protein compositions for removal of immunogenic aggregates
FR3040882A1 (fr) * 2015-09-10 2017-03-17 Lab Francais Du Fractionnement Composition liquide d'albumine humaine a usage therapeutique
CN115039180B (zh) * 2020-01-30 2026-06-19 费森尤斯医疗保健控股公司 用于透析毒素置换剂化合物的建模和优化技术
US12629445B2 (en) 2020-03-20 2026-05-19 Bard Peripheral Vascular, Inc. Reactive hydrogel forming formulations and related methods, including methods of preparation
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
WO2022146917A1 (en) 2020-12-28 2022-07-07 Davol Inc. Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent
JP2024088949A (ja) * 2022-12-21 2024-07-03 Kmバイオロジクス株式会社 生体高分子溶液のろ過方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019919D0 (en) 1990-09-12 1990-10-24 Delta Biotechnology Ltd Purification of proteins
FR2672604B1 (fr) * 1991-02-07 1995-05-05 Pasteur Merieux Serums Vacc Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue.
US5849874A (en) * 1991-07-12 1998-12-15 Gist-Brocades, N.V. Process for the purification of serum albumin
US5440018A (en) 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
JPH06279296A (ja) * 1993-03-25 1994-10-04 Asahi Chem Ind Co Ltd 血漿分画製剤中から蛋白質会合物の除去方法
SE9500724D0 (sv) * 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
CN1275981C (zh) * 2000-10-24 2006-09-20 财团法人化学及血清疗法研究所 人血清白蛋白多聚体的单体化方法
JP4798832B2 (ja) * 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 ヒト血清アルブミン多量体の除去方法
US6806355B2 (en) * 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
DE10211632A1 (de) * 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
CA2524246C (en) * 2003-04-09 2014-10-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Process for producing albumin preparations comprising virus-removing filtration
FR2866890B1 (fr) * 2004-02-27 2008-04-04 Lab Francais Du Fractionnement Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant

Also Published As

Publication number Publication date
CY1107082T1 (el) 2012-10-24
PT1718673E (pt) 2007-12-13
CA2557174A1 (fr) 2005-09-29
JP2012102115A (ja) 2012-05-31
FR2866890A1 (fr) 2005-09-02
DE602005002461D1 (de) 2007-10-25
FR2866890B1 (fr) 2008-04-04
US20070161122A1 (en) 2007-07-12
DK1718673T3 (da) 2008-01-14
EP1718673B1 (fr) 2007-09-12
IL177286A (en) 2012-08-30
IL177286A0 (en) 2006-12-10
AU2005223418A1 (en) 2005-09-29
WO2005090402A1 (fr) 2005-09-29
AU2005223418B2 (en) 2008-12-18
US20170166626A1 (en) 2017-06-15
US10562957B2 (en) 2020-02-18
ES2294696T3 (es) 2008-04-01
DE602005002461T2 (de) 2008-06-12
CA2557174C (fr) 2013-04-30
US20150152162A1 (en) 2015-06-04
JP2007535495A (ja) 2007-12-06
EP1718673A1 (fr) 2006-11-08
PL1718673T3 (pl) 2008-03-31
JP4979571B2 (ja) 2012-07-18
US9611311B2 (en) 2017-04-04
ATE373014T1 (de) 2007-09-15

Similar Documents

Publication Publication Date Title
CY1107082T1 (el) Μεθοδος καθαρισμου αλβουμινης η οποια περιλαμβανει ενα σταδιο νανοδιηθησης, διαλυμα και συνθεση για θεραπευτικη χρηση που περιεχουν την ιδια
DE602005020269D1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
DE60228961D1 (de) Verfahren zur herstellung von l-aminosäuren durch enterobacteriaceae-stämmen mit verstärkter expression des mop-b
SE0301010D0 (sv) Novel compounds
SE0301009D0 (sv) Novel compounds
DE602004012745D1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
DE502005010476D1 (de) Verfahren zur herstellung von adipodinitril durch hydrocyanierung von 1,3-butadien
EP2628746A3 (en) A process for concentration of a polypeptide
ATE489105T1 (de) Faktor ixa zur behandlung von blutungsstörungen
DE60209537D1 (de) Neue kristalline formen von meloxicam, deren herstellung und verfahren zu deren umwandlung ineinander
DE60322727D1 (de) Rückgefaltetes Membranprotein in monodisperser Form
ATE376997T1 (de) Verfahren zur herstellung von 1,4- diphenylazetidinon-derivaten
ATE465998T1 (de) Verfahren zur herstellung und reinigung von 1,7'- dimethyl-2'-propyl-2,5'-bi-1h-benzimidazol
PL1654284T3 (pl) Sposób uzyskiwania roztworu alfa-1-antytrypsyny
DE502005000428D1 (de) Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen
ATE424892T1 (de) Verfahren zur herstellung von derivaten des 4a,5, 9,10,11,12-hexahydrobenzofuro ä3a,3,2üä 2 ü- benzazepins
BRPI0416637A (pt) método para produção de uma solução aquosa de etanolamina de cobre e de uma solução de monoetanolamina de cobre
EA200800785A1 (ru) 4-арил-1,4-дигидро-3(2н)-изохинолиноны и 4-арил-1,2,3,4-тетрагидроизохинолины в качестве ингибиторов igf-1r и в качестве фармакологического средства в тест-системах, фармацевтическая композиция и изделие на их основе и способ лечения заболеваний, опосредованных igf-1 рецептором
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
ATE341558T1 (de) Verfahren zur herstellung von topiramate
DE602004023534D1 (de) Verfahren zur herstellung von optisch aktivem 2-alkylcystein, derivate davon und herstellungsverfahren
BR0308753A (pt) Método para produzir pseudo-ilhotas
RU2003118497A (ru) Способ лечения заболеваний слизистых оболочек
DE602006013688D1 (de) Neues verfahren zur herstellung von thoc
ATE457994T1 (de) Verfahren zur aufreinigung von vancomycin

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time